Analyst Ratings for Regeneron Pharma (REGN)

Overall Rating: BUY Rating Trend:

Avg. $ Target: $163.53 (-32.6%)

Date	Firm	Type	Rating (Past)	PT (Past)	Start $	End $	% Chg.	Details
5/17/2013	UBS	New Coverage	Neutral (N/A)	290.00 (N/A)	264.66	242.76	-8.27%	Details
5/3/2013	Brean Capital	Upgrade	Buy (Hold)	315.00 (N/A)	248.63	242.76	-2.36%	Details
5/2/2013	JMP Securities	Upgrade	Market Outperform (Market Perform)	N/A (N/A)	237.29	242.76	2.31%	Details
2/28/2013	Barclays	New Coverage	Overweight (N/A)	194.00 (N/A)	164.80	242.76	47.31%	Details
1/15/2013	Jefferies	Downgrade	Hold (Buy)	179.00 (179.00)	179.40	242.76	35.32%	Details
11/13/2012	Credit Suisse	New Coverage	Outperform (N/A)	187.00 (N/A)	144.90	242.76	67.54%	Details
8/7/2012	Lazard Capital	New Coverage	Neutral (N/A)	N/A (N/A)	137.45	242.76	76.62%	Details
7/25/2012	BMO Capital	Upgrade	Outperform (Market Perform)	158.00 (143.00)	121.44	242.76	99.9%	Details
4/2/2012	Goldman Sachs » Updated 4/9/2013	New Coverage	Buy (N/A)	215.00 (196.00)	116.62	242.76	108.16%	Details
2/6/2012	Piper Jaffray	Downgrade	Neutral (N/A)	81.00 (N/A)	4.14	242.76	5763.77%	Details
2/3/2012	ThinkEquity	New Coverage	Buy (N/A)	120.00 (N/A)	95.01	242.76	155.51%	Details
1/30/2012	BofA/Merrill Lynch	Upgrade	Buy (N/A)	N/A (N/A)	85.54	242.76	183.8%	Details
1/17/2012	Roth Capital	Downgrade	Neutral (N/A)	78.00 (N/A)	78.92	242.76	207.6%	Details
1/10/2012	Baird » Updated 1/15/2013	Upgrade	Outperform (N/A)	205.00 (176.00)	65.48	242.76	270.74%	Details
10/26/2011	Leerink Swann » Updated 4/3/2013	Upgrade	Outperform (N/A)	190.00 (185.00)	57.09	242.76	325.22%	Details

Like REGN Ratings? Also take a look at SNY, AGN, VRSK, NFLX